Krystal Biotech (KRYS) Cash & Equivalents (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Cash & Equivalents data on file, last reported at $501.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 62.36% year-over-year to $501.3 million; the trailing twelve-month figure through Mar 2026 stood at $501.3 million (up 62.36% YoY), and the FY2025 full-year result was $496.3 million, up 43.91% from the prior year.
• Cash & Equivalents climbed to $501.3 million in Q1 2026, from $496.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $501.3 million in Q1 2026 to a low of $140.7 million in Q1 2023.
• A 5-year average of $321.2 million and a median of $345.8 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 52.56% in 2022 and surged 155.08% in 2024, its largest moves.
• Tracing KRYS's Cash & Equivalents over 5 years: stood at $161.9 million in 2022, then surged by 121.33% to $358.3 million in 2023, then dropped by 3.76% to $344.9 million in 2024, then soared by 43.91% to $496.3 million in 2025, then gained by 1.01% to $501.3 million in 2026.
• Business Quant data shows KRYS's Cash & Equivalents at $501.3 million in Q1 2026, $496.3 million in Q4 2025, and $392.6 million in Q3 2025.